This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Sacral Spina Bifida with Hydrocephalus수두증을 동반한 천추 이분척추 (수두증 반 천추 이분척추)

Contents and key points
ItemDetails
A. Classification codesICD-10: Q05.3 | Special Copayment Reduction: V179
B. SynonymsSacral spina bifida with hydrocephalus
C. Adult onsetVery low — as a congenital spinal malformation, it is in principle diagnosed in the fetal or neonatal period; first onset in adulthood is extremely rare.
1. HistoryHistory of spina bifida; discovery of folic acid prevention (1991); MOMS fetal surgery trial (2011).
2. CausesFolate deficiency, multifactorial inheritance, maternal diabetes, obesity, anticonvulsants; hydrocephalus: Chiari II malformation.
3. GeneticsMTHFR, PCP pathway; multifactorial inheritance; recurrence risk 2–5%; high-dose folic acid prevention.
4. General epidemiology1 in 1,000–2,000 births; Special Copayment Reduction V179; slight sex difference.
5. PathophysiologyFailure of neural tube closure; two-hit theory; mechanisms of Chiari II malformation and hydrocephalus.
6. SymptomsLower limb paralysis (by level), hydrocephalus symptoms, neurogenic bladder and bowel
7. SignsCystic defect at the lesion site; neurological findings; signs of hydrocephalus (if present)
8. ScreeningMSAFP, detailed prenatal ultrasound (lemon and banana signs), fetal MRI.
9. DiagnosisPrenatal confirmation; postnatal neurological, imaging, urological, and orthopedic evaluation.
10. TreatmentSpinal cord closure (prenatal/postnatal); hydrocephalus shunt (if present); CIC; rehabilitation.
11. PrognosisSacral: most favorable; independent ambulation about 80–90%; management of neurogenic bladder essential
12. PreventionFolic acid (general 400–800 μg; high-risk 4,000 μg); risk factor management.
13. ReferencesMitchell LE et al. 2004 and 9 other references

1. History

Spina bifida is one of the oldest congenital malformations in the history of human medicine. The term 'spina bifida' is known to have been first used in 1641 by the 17th-century Dutch physician Nicolaas Tulp (1593–1674), expressing in Latin the condition of a vertebra split in two. In the early 18th century, the Italian anatomist Giovanni Battista Morgagni described in detail the pathological anatomy of spina bifida and its association with hydrocephalus. In the 19th century, surgical treatment was attempted, but results were poor because of infection and technical limitations.

In the mid-20th century, the introduction of the ventriculoperitoneal shunt (VP shunt) and antibiotics dramatically improved treatment outcomes for spina bifida with hydrocephalus. In 1965, Hibbard and Smithells first proposed an association between folate deficiency and neural tube defects, and in 1991 the UK MRC Vitamin Study confirmed in a randomized controlled trial that folic acid supplementation before pregnancy reduces recurrence of neural tube defects by about 72%. Mandatory folic acid fortification of grain products was subsequently implemented in many countries, significantly lowering the incidence of spina bifida.

In prenatal diagnosis, the introduction of maternal serum alpha-fetoprotein (MSAFP) testing in 1972 and the spread of high-resolution prenatal ultrasound from the 1980s onward meant that most open spina bifida came to be diagnosed prenatally. The MOMS randomized controlled trial published in 2011 demonstrated that prenatal myelomeningocele closure (fetal surgery) significantly improves neurological outcome compared with postnatal surgery, shifting the paradigm of spina bifida treatment. Today, the worldwide standard for spina bifida management is collaboration among pediatric neurosurgery, neurology, urology, orthopedics, rehabilitation medicine, and developmental pediatrics within a multidisciplinary spina bifida clinic.

Thoracic/lumbar/sacral/unspecified spina bifida with hydrocephalus differ in clinical characteristics depending on lesion level, and each is classified under its own ICD-10 code (Q05.1–Q05.4). In Korea, multidisciplinary spina bifida clinics are also operated mainly at major children's hospitals, and registration under Special Copayment Reduction V179 allows medical cost support.


2. Causes

Spina bifida is a neural tube defect (NTD) caused by failure of the neural tube closure process in early pregnancy (about 17–30 days after fertilization, 5–6 weeks of gestation). Its causes are divided into genetic factors, maternal nutritional and metabolic factors, environmental factors, and multifactorial interactions.

Folate deficiency: folic acid deficiency in early pregnancy is the most important preventable risk factor for spina bifida. Folic acid is an essential nutrient for DNA synthesis, cell division, and one-carbon metabolism, and adequate folic acid intake before and in early pregnancy (400–800 μg per day; 4,000 μg for high-risk groups) lowers the incidence of spina bifida by about 50–70%.

Genetic factors: spina bifida is a multifactorial disease; the MTHFR 677C→T polymorphism, folate receptor gene variants, and variants in planar cell polarity (PCP) pathway genes (VANGL1, VANGL2, etc.) are associated with increased risk of spina bifida. With a family history, the recurrence risk is about 4–8 times that of the general population.

Maternal factors: maternal diabetes (poor glycemic control in early pregnancy), maternal obesity (BMI > 30), use of anticonvulsants (valproic acid, carbamazepine), and high fever in early pregnancy (38°C or higher) increase the risk of spina bifida.

Etiology of hydrocephalus: hydrocephalus arises through combined mechanisms including Chiari II malformation (herniation of the cerebellum and brainstem through the foramen magnum), aqueductal stenosis, and fourth ventricle outlet obstruction. The higher the lesion level, the more severe the Chiari II malformation and the higher the rate and severity of associated hydrocephalus.


3. Genetics

Spina bifida is a disease of multifactorial inheritance, arising from complex interactions of multiple genetic polymorphisms and environmental factors rather than a single gene mutation. The risk of recurrence within families is higher than in the general population, but it does not follow a typical Mendelian pattern of inheritance.

Folate metabolism genes: the MTHFR c.677C→T polymorphism (p.Ala222Val) reduces enzyme activity and raises blood homocysteine, increasing the risk of spina bifida about 1.5–2-fold. Variants in folate metabolism enzyme genes such as FOLR1 (folate receptor 1) and MTHFD1 are also associated with neural tube defects.

PCP pathway genes: VANGL1, VANGL2, CELSR1, FZD3, and others are essential for convergent extension movements during neural tube closure, and variants in these genes are found in about 1–3% of patients with spina bifida.

Recurrence risk: 1 child with spina bifida: recurrence risk in the next pregnancy about 2–5%. 2 affected: about 10–15%. One parent affected: about 4–8% for children. In high-risk groups, high-dose folic acid (4,000 μg/day) supplementation from before pregnancy greatly reduces the risk of recurrence.


4. General epidemiology

Spina bifida is the most common neural tube defect worldwide, occurring in about 1 in 1,000–2,000 births. Incidence by country differs greatly depending on folic acid supplementation policies and the rate of pregnancy termination after prenatal diagnosis. For spina bifida with hydrocephalus (Q05.0–Q05.4), hydrocephalus accompanies about 80–90% of all open spina bifida. The incidence in Korea is estimated at about 4–6 per 10,000 births, and registration under Special Copayment Reduction V179 allows medical cost support. Sex differences are slight, and it occurs in all ethnic groups worldwide.


5. Pathophysiology

Spina bifida arises from failure of neural tube closure at about 17–30 days of gestation; neural tube closure is a zipper-like process proceeding simultaneously from several initiation sites. The level of spina bifida (cervical/thoracic/lumbar/sacral) is determined by the site of closure failure. Two-hit hypothesis: ① the primary developmental defect due to failure of neural tube closure + ② secondary damage from exposure to amniotic fluid in utero cause the neurological impairment. Chiari II malformation arises from abnormal posterior fossa development due to herniation of the spinal cord and causes non-communicating hydrocephalus through impaired cerebrospinal fluid flow. Neurogenic bladder arises from loss of sacral nerve (S2–S4) function below the lesion.


6. Symptoms

Sacral spina bifida has the lowest spinal lesion among the forms of spina bifida, and lower limb function is often relatively well preserved. However, when hydrocephalus is present (Q05.3), symptoms related to increased intracranial pressure and Chiari II malformation are added.

Lower limb function: with lesions at the sacral (S1–S4) level, the function of the ankle and foot is mainly affected. S1 lesions: weakness of plantar flexion, weakness of the calf muscles, foot deformities (pes cavus, clubfoot). S2–S3 lesions: toe deformities (claw toes) due to paralysis of the intrinsic foot muscles. Lower limb strength is relatively well preserved, so many patients can walk independently, but orthoses may be needed because of foot deformities and balance problems.

Neurogenic bladder: due to loss of sacral nerve (S2–S4) function, neurogenic bladder develops in almost all patients with sacral spina bifida. Decreased bladder contractility (flaccid bladder), urinary incontinence, residual urine, and urinary tract infections are the main problems. Management of neurogenic bladder is essential even in patients whose gait outwardly appears normal.

Neurogenic bowel: constipation and fecal incontinence occur due to weakness of the anal sphincter and loss of bowel sensation. Regular bowel management is needed.

Symptoms of hydrocephalus: when hydrocephalus is present (Q05.3), symptoms of increased intracranial pressure (headache, nausea·vomiting, papilledema) appear. In sacral spina bifida, hydrocephalus tends to be less severe than with cervical, thoracic, or lumbar lesions, but active treatment is still needed.

Loss of skin sensation: loss of sensation in the perineum, perianal area, and soles of the feet creates a risk of not noticing pressure ulcers, foot injuries, and infections.


7. Signs

The physical signs of sacral spina bifida tend to be milder than those of lumbar spina bifida, and relatively good preservation of lower limb function is characteristic.

Neurological signs: loss of the ankle reflex (achilles reflex), weakness of plantar muscle strength, weakness of toe flexion, and paralysis of the intrinsic foot muscles are observed. Loss of the anal reflex, weakness of the anal sphincter, and loss of perineal sensation are characteristic. Walking is possible, but gait abnormalities due to foot deformities (pes cavus, clubfoot, claw toes) may occur.

Orthopedic signs: foot deformities (pes cavus, clubfoot) are common, and hip dislocation is rare in sacral spina bifida. Lower limb muscle atrophy is observed in the foot and calf regions. Spinal deformity (scoliosis) is rarer than with lumbar or thoracic lesions.

Signs of hydrocephalus: when hydrocephalus is present, macrocephaly, a bulging fontanelle, and the sunset sign may appear in infants. In sacral spina bifida, symptoms related to Chiari II malformation (dysphagia, apnea) tend to be milder than with cervical or thoracic lesions.

Imaging findings: MRI confirms myelomeningocele at the sacral level and tethered cord. When hydrocephalus is present, brain MRI shows ventricular enlargement and Chiari II malformation. Urologic ultrasound assesses bladder abnormalities and the presence of hydronephrosis.


8. Screening

Prenatal screening for spina bifida follows a stepwise approach: maternal serum alpha-fetoprotein (MSAFP, 15–22 weeks of gestation; positive threshold ≥ 2.0–2.5 MoM), detailed prenatal ultrasound at 18–22 weeks (spinal defect, lemon sign, banana sign, ventriculomegaly), and additional fetal MRI if abnormal. Prenatal ultrasound has a sensitivity of 95% or higher for detecting open spina bifida. Fetal MRI precisely assesses the lesion level, degree of Chiari II malformation, and severity of hydrocephalus, providing important information for surgical decisions and prognostic counseling. Amniotic fluid AFP and AChE testing is performed as an adjunct when ultrasound findings are unclear.


9. Diagnosis

Diagnosis of spina bifida is confirmed prenatally by a stepwise approach of prenatal MSAFP → detailed ultrasound → fetal MRI, and completed after birth by neurological evaluation, brain and spine MRI, urological evaluation, and orthopedic evaluation. Immediately after birth, motor and sensory function below the lesion level, the anal reflex, and bladder function are evaluated to establish the extent of loss of neurological function. Brain MRI identifies hydrocephalus, Chiari II malformation, and associated brain malformations, and spinal MRI evaluates the lesion level, tethered cord, and syringomyelia. Urodynamic testing characterizes the neurogenic bladder and determines the indications for starting CIC.


10. Treatment

Treatment of spina bifida with hydrocephalus requires a multidisciplinary approach including prenatal or postnatal spinal cord closure, hydrocephalus surgery (VP shunt or ETV), neurogenic bladder management (CIC, anticholinergics), orthopedic treatment, and neurodevelopmental support. Prenatal surgery (fetal surgery): based on the MOMS trial (2011), performed at 19–25 weeks of gestation in selected cases; it reverses Chiari II malformation, reduces the need for shunting, and improves lower limb motor function. Postnatal surgery: closure of the spinal defect within 24–48 hours. Treatment of hydrocephalus: VP shunt or ETV. Neurogenic bladder: CIC + anticholinergics (key to protecting renal function). Orthopedics: orthoses, surgical correction. Rehabilitation: physical therapy, occupational therapy, speech therapy, neuropsychological assessment, and learning support.


11. Prognosis

Sacral spina bifida is the type of spina bifida with the best prognosis. Lower limb function is relatively well preserved, and independent ambulation is possible in most patients. However, neurogenic bladder and bowel dysfunction persist in most patients, and ongoing management of these is a key element of long-term prognosis.

Ambulation prognosis: about 80–90% of patients with sacral lesions achieve independent ambulation, often living without orthoses or with only a minimal AFO. Orthopedic correction of foot deformities greatly improves gait quality.

Renal function prognosis: even in sacral spina bifida, there is a risk of renal function damage due to neurogenic bladder. Early, active bladder management using CIC and anticholinergics can effectively prevent renal damage. During long-term follow-up, urodynamic studies and renal ultrasound are performed regularly to monitor renal function.

Intellectual function: when hydrocephalus is present, many patients maintain normal intelligence if it is appropriately treated with early shunting. In sacral spina bifida, learning disabilities are less common than in higher-level spina bifida, but attention deficits and visuospatial processing disorders may be observed.

Prognosis of hydrocephalus: when hydrocephalus is controlled with early shunting or ETV, the cognitive prognosis is good. Ongoing follow-up for shunt complications is needed.


12. Prevention

The most effective primary prevention of spina bifida is folic acid supplementation before and in early pregnancy. General population: 400–800 μg daily from 1 month before pregnancy until 12 weeks of gestation. High-risk groups (previous NTD pregnancy, family history, diabetes, anticonvulsant use): high-dose 4,000 μg daily from before pregnancy until 12 weeks of gestation. Management of risk factors before pregnancy: glycemic control in maternal diabetes, obesity management, substitution or dose minimization of anticonvulsants such as valproic acid, and avoidance of high fever in early pregnancy. Prenatal care: MSAFP screening, detailed ultrasound, fetal MRI, and pregnancy and delivery planning with the multidisciplinary team. Prevention of complications: early surgery (spinal cord closure, shunting), early introduction of CIC, and regular multidisciplinary follow-up for early detection and management of shunt malfunction, spinal cord retethering, and urological complications.

13. References

  1. Mitchell LE, Adzick NS, Melchionne J, et al. Spina bifida. Lancet. 2004;364(9448):1885-1895. PMID: 15555669.
  2. Adzick NS, Thom EA, Spong CY, et al. A randomized trial of prenatal versus postnatal repair of myelomeningocele. N Engl J Med. 2011;364(11):993-1004. PMID: 21306277.
  3. Copp AJ, Stanier P, Greene NDE. Neural tube defects: recent advances, unsolved questions, and controversies. Lancet Neurol. 2013;12(8):799-810. PMID: 23790957.
  4. Northrup H, Volcik KA. Spina bifida and other neural tube defects. Curr Probl Pediatr. 2000;30(10):313-332. PMID: 11147289.
  5. Blount JP, Bowman R, Dias MS, et al. Neurosurgery in spina bifida. J Pediatr Rehabil Med. 2020;13(4):565-576. PMID: 33252094.
  6. Bowman RM, McLone DG, Grant JA, et al. Spina bifida outcome: a 25-year prospective. Pediatr Neurosurg. 2001;34(3):114-120. PMID: 11359098.
  7. Liptak GS, Dosa NP. Myelomeningocele. Pediatr Rev. 2010;31(11):443-450. PMID: 21041162.
  8. Bol KA, Collins JS, Kirby RS. Survival of infants with neural tube defects in the presence of folic acid fortification. Pediatrics. 2006;117(3):803-813. PMID: 16510665.
  9. Jukic AM, Wilcox AJ, Lie RT, et al. Spina bifida and the risk of stillbirth in Norway. Am J Epidemiol. 2004;160(10):1001-1008. PMID: 15522861.
  10. Williams LJ, Rasmussen SA, Flores A, et al. Decline in the prevalence of spina bifida by race/ethnicity. Pediatrics. 2005;116(3):580-586. PMID: 16140698.